CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 196 enrolled
Drug / intervention
Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01657461
NCT01657461N/ACompleted
CompareCT.gov

Solitaire™ FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial

Medtronic Neurovascular Clinical Affairs·interventional·Posted Aug 6, 2012·Updated May 18, 2017

In Brief

A clinical study evaluating Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) and Solitaire revascularization device for Acute Ischemic Stroke. Completed, enrolled 196 participants across 1 site.

Detailed Summary

The primary study objective is to determine if subjects experiencing an acute ischemic stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization Device within 6 hours of symptom onset have less stroke-related neurological disability (mRS) than those subjects treated with IV t-PA alone

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 6, 2012
Enrollment StartDec 1, 2012
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 13.9 years ago

Interventions

Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)drug

Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)

Solitaire revascularization devicedevice

Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator